Shared Pages

Michael A. Mussallem, age 55, has been chairman and CEO since 2000. Prior to 2000, Mussallem held a variety of positions with increasing responsibility in engineering, product development and senior management at Baxter International Inc., including Group Vice President of its CardioVascular business from 1994 to 2000 and Group Vice President of the Biopharmaceutical business from 1998 to 2000. From 1996 until 1998, he was the Chairman of Baxter's Asia Board overseeing Baxter's operations throughout Asia. Mussallem received his Bachelor of Science degree in chemical engineering from Rose-Hulman Institute of Technology and was conferred an honorary doctorate by his alma mater in 1999. Mussallem is chairman of the board of directors of the Advanced Medical Technology Association (AdvaMed), and serves as a member of the board for Advanced Medical Optics, Inc.  He is also on the boards and executive committees of the California Healthcare Institute and OCTANe, and is a member of the University of California, Irvine, Chief Executive Roundtable.  He received a bachelor’s degree in chemical engineering in 1974 and an honorary doctorate in 1999 from the Rose-Hulman Institute of Technology in Terre Haute, Indiana.

Anita B. Bessler, age 60. From 2000 to 2001, she served as Corporate Vice President, Cardiac Surgery of the company. Bessler joined Baxter in 1988 as Vice President and General Manager of Sales and Marketing for Baxter’s Hyland division, and in 1991 became President, Cardiac Surgery for Baxter’s CardioVascular business. Prior to her tenure with Baxter, from 1986 until 1988 she was Senior Executive Vice President with the USV/Armour Pharmaceutical Division of Rhone Poulenc Rohrer. From 1976 until 1986, Bessler held senior management positions with Revlon’s Healthcare Group. She is a graduate of Indiana University, where she earned a Bachelor of Science degree in marketing and economics.

Stuart L. Foster, age 57. Foster joined Baxter’s CardioVascular Group in 1994 as President of the Vascular businesses. In 1997, his responsibilities increased to include global oversight responsibilities for the Critical Care business. He also was responsible for all international operations of the CardioVascular businesses and led the CardioVascular business’ Technology Innovation Team. From 2000 to 2001, he served as Corporate Vice President, Global Operations for the company. In 2001, he assumed his current role, which includes management of Research & Development, Discovery and Regulatory & Clinical Affairs. Prior to joining Baxter, Foster was Chief Executive Officer and President of Intramed Laboratories, acquired by Baxter in 1994, and an executive with SensorMedics Corporation, a medical device company that he co-founded. Foster received his Bachelor of Science degree in biomedical engineering from Rensselaer Polytechnic Institute and earned his master’s degree from the University of Southern California.

John H. Kehl Jr., age 54. Kehl held various positions of increasing responsibility at Baxter since joining its Treasury department in 1975. In 1980, he was promoted to Manager of Investor Relations and Communications and, in 1985, assumed responsibility for directing all aspects of Baxter’s external communications. Kehl was appointed Vice President, Controller for Baxter’s CardioVascular business in 1988 with responsibility for Finance, Information Systems and Business Planning. He became Vice President of Business Development in 1995. Kehl also served on Baxter’s Japan Board. He earned his Bachelor of Arts degree in business and economics from Loras College and received his MBA from Loyola University in Chicago.

John “Alex” Martin, age 55. He joined Edwards from Cordis Corporation, a Johnson & Johnson company, where he most recently served as Senior Vice President, International. He previously served as Cordis’ Vice President of Sales and Marketing, with responsibility for all U.S. coronary therapeutic and diagnostic device sales. Under his leadership, the company experienced significant growth and became the leader in its market. Prior to joining Cordis, Martin served in sales, marketing and business development management positions at several organizations, including C.R. Bard’s USCI division and IMED Corporation. He also served as Director of the Emergency Medical Services at The Medical Center at Bowling Green. Martin holds a bachelor’s degree from the University of Kentucky at Lexington.

Paul C. Redmond, age 45, is responsible for the global CardioVations Surgical Systems operations at Edwards, executing on the company's growth vision for minimally invasive heart valve surgery. With more than 22 years of experience, the vast majority at a senior level within the medical device industry, Redmond most recently served as General Manager of Edwards' Vascular business, with responsibility for Edwards' global Base Vascular and Peripheral Vascular Stent (PVS) operations. Prior to joining Edwards, Redmond was Vice President, CardioVascular Technologies, at Cordis Cardiology, a Johnson & Johnson company. In this position, he was responsible for the leadership of the CVT business unit and had the oversight of planning, coordination and execution of product management and marketing activities, sales, manufacturing and supply chain for CVT products. Redmond also served as Vice President, New Product Development, at Cordis and has worked for BMR Neurotech, Boston Scientific and other companies in the U.S. and Europe. Redmond received his B.A. in Mathematics and a B.Eng in Mechanical Engineering from Trinity College in Dublin, Ireland, and also completed the IEP program at I.N.S.E.A.D, the renowned international business program in Paris and Singapore.

Stanton J. Rowe, age 56. He previously served as President and CEO of Percutaneous Valve Technology Inc., which was acquired by Edwards in January 2004. Prior to PVT, which he helped to found in 1999, Rowe was Corporate Vice President of Business Development and Strategic Planning for Datascope Corp. Prior to this, he was Vice President of Business Development for Johnson & Johnson’s Interventional Systems Division (JJIS), responsible for the company’s coronary stent development efforts. At JJIS and the related Cordis Corporation, Rowe held a variety of positions with increasing levels of responsibility, including heading the company’s Business Development, Advanced Technology, Worldwide Clinical Research, and Marketing groups. Rowe joined Cordis after having held several positions in product management for various medical device companies. He holds a bachelor’s degree from the University of Alabama. He also sits on the Board of Directors of both Remon Medical Ltd. and Biomerix Corp.

Patrick B. Verguet, age 50. Most recently, he served as Edwards’ Vice President of Sales and Country Management in Europe. Verguet is a doctor in Pharmacy and started his career 21 years ago with Travenol in France, and held several sales and marketing management positions within Baxter Europe prior to the company’s spin-off from Baxter. Over the years, he served as Global Business Director for hemofiltration and Business Unit / Country Manager for Edwards' operations in the United Kingdom, France, Switzerland, Belgium, Netherlands, and Nordic Countries. Verguet also served as General Manager of Edwards’ Research Medical operations in Utah, and as Vice President and General Manager of Edwards’ Cardiac Surgery Systems franchise in Irvine.

Larry Wood, age 42, is responsible for the company’s key initiatives in transcatheter heart valve replacement. These responsibilities include a team in Irvine as well as the PVT Limited facility in Israel. Most recently, from March 2004 to February 2007, Wood served as Vice President and General Manager responsible for the valve replacement programs within the Percutaneous Valve Interventions department. Wood joined the Edwards organization in 1985, progressing through a variety of increasingly responsible positions including various manufacturing management positions as well as regulatory affairs. At the time of the spin off from Baxter International, he was Senior Director of Regulatory Affairs and Clinical Studies for the Heart Valve franchise. From 2001 to 2004, Wood was the vice president in Global Franchise Management with responsibilities for Strategic and Clinical Marketing. Wood holds a bachelor’s degree in Business and an MBA from Pepperdine University.

Thomas M. Abate, age 54. Prior to his assuming his current role in 2006, Abate had been operating as Edwards' Corporate Controller, and served an instrumental role in the company's spin-off from Baxter in 2000. He previously served as Group Controller for Baxter's CardioVascular Group and also worked in a global capacity as Vice President of Finance for Clintec International, a joint venture with Baxter and Nestle based in Lausanne, Switzerland. Abate, who earned a bachelor's degree in accounting from the University of Illinois and an MBA from Northern Illinois University, served in a series of finance positions of increasing responsibility during his tenure at Baxter since 1982 and at Edwards.

Donald E. Bobo, Jr., age 46, is responsible for the surgical heart valve business, including tissue replacement and repair devices. Bobo has over 20 years of experience in the medical products and healthcare industry where he most recently served as Edwards’ Vice President and General Manager of Transcatheter Mitral Repair and as Vice President, Corporate Strategy. Prior to joining Edwards Lifesciences, he served as Director/GM of the Non-Invasive Monitoring Business Unit of InnerSpace, a medical device startup company. Lastly, from 2001 to 2006, Bobo served as a Director and board member of PLC Medical, a publicly traded medical device company located in Boston, MA. Bobo holds a bachelor's degree in mathematics and a master's degree in engineering.

Bruce P. Garren, age 61, has been General Counsel since 2000. Previously, he was Senior Vice President-General Counsel for Safeskin Corporation, a San Diego-based manufacturer of latex and synthetic gloves for the healthcare and scientific markets. Prior to that he was Vice President-General Counsel of Tambrands Inc., now part of The Procter & Gamble Company. Garren was with the law firm of Arnold & Porter in Washington, D.C. from 1980 to 1985. He received his undergraduate degree from Antioch College and his law degree from Cornell Law School.

Corinne H. Lyle, age 48. Prior to assuming her current position in 2006, Lyle served as chief financial officer and treasurer. Before joining Edwards in 2003, Lyle was on the Board of Directors for Edwards Lifesciences and Vice President, Chief Financial Officer of Tularik, Inc., a company involved in the discovery and development of drugs based on gene regulation and sold to Amgen, Inc. in 2004. Prior to joining Tularik, she was Executive Director- Health Care Group at Warburg Dillon Read LLC in San Francisco, an investment bank. Lyle received her undergraduate degree in industrial engineering from Stanford University and her MBA from Harvard Business School. Lyle is a director of Neurocrine Biosciences, Inc. and Onyx Pharmaceuticals, Inc.

John P. McGrath, age 48. McGrath joined Edwards in 2006 as Vice President of Quality with more than twenty years of medical device and combination product experience in quality, manufacturing and product development. McGrath was previously Vice President of Quality at Cordis Corporation, where his quality assurance responsibilities included cardiovascular, endovascular and neurovascular businesses. Prior to joining Cordis he was director of quality at CR Bard’s USCI and Electrophysiology divisions. McGrath received his undergraduate degree from Trinity College, Dublin, Ireland, an MSc in Total Quality Management from Sheffield Hallam University, United Kingdom and his PhD in Management from California Coast University.

Robert C. Reindl, age 53. From 1993 through 1995 Reindl was Director of Baxter's Institute for Training and Development, and from 1995 through 1997, he was Vice President of Baxter's Institute for Training and Development. In 1997, he became Vice President, Human Resources, for Baxter's CardioVascular business. From 1987 until 1993, Reindl was a Manager with Arthur Andersen & Co., where he consulted internally on a variety of human resource and organizational development issues, as well as designed management development training. Prior to this, he was a communications instructor for Marietta College and Ohio University. Reindl earned his Bachelor of Science degree in communication from the University of Wisconsin-Stevens Point and his master's degree from Bowling Green State University in Ohio.

Carlyn D. Solomon, age 45, corporate vice president, Critical Care and Vascular, is responsible for Edwards Lifesciences’ global market-leading Critical Care business, as well as its base Vascular business. Solomon has 25 years of leadership experience in the medical device, biotechnology and pharmaceutical industries. Prior to joining Edwards in June 2005, he served in a number of positions with increasing responsibility at Baxter Healthcare Corporation, including interim president of the company’s $3 billion BioScience Division, vice president of Global Manufacturing, and vice president of Global Operations. During his tenure at Baxter, the organization received numerous awards for manufacturing and operational excellence, and was instrumental in developing revolutionary technologies. Solomon has served as an executive board member for the California Manufacturers and Technology Association and the Plasma Protein Therapeutics Association. He also served on the board of directors for The Baxter International Foundation. Solomon earned a bachelor’s degree in industrial engineering from Kansas State University.

Huimin Wang, M.D., age 50. Previously, Dr. Wang was a representative director of Baxter Limited, a Japan corporation, through September 2002. Wang joined Baxter in 1993 and served as a Senior Manager of Strategy Development and, later, Director of Product/Therapy for Baxter’s Renal Division in Japan. In 1997, he became President of Medical Systems and Devices, responsible for both the Cardiovascular and Intravenous Systems businesses in Japan. Prior to joining Baxter, Wang was a Senior Associate with Booz, Allen & Hamilton in Chicago; Vice President of Integrated Strategies Inc., a consulting and venture management firm he co-founded; and an Associate with McKinsey & Company. From 1981 until 1986, Wang was a Resident and Staff Physician in anesthesiology at Keio University Hospital in Tokyo. In 2006, Wang was appointed as Visiting Associate Professor for Keio University's department of anesthesiology. Wang earned his doctor of medicine degree from Kagoshima University in Japan, and his MBA from the University of Chicago.